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Purpose: To investigate whether histogram analysis of the hepatobiliary phase on 
gadoxetate enhanced-MRI could be used as a quantitative index for determination of 
liver cirrhosis. Materials and Methods: A total of 63 patients [26 in a normal liver 
function (NLF) group and 37 in a cirrhotic group] underwent gadoxetate-enhanced 
MRI, and hepatobiliary phase images were obtained at 20 minutes after contrast in-
jection. The signal intensity of the hepatic parenchyma was measured at four differ-
ent regions of interest (ROI) of the liver, avoiding vessels and bile ducts. Standard 
deviation (SD), coefficient of variation (CV), and corrected CV were calculated on 
the histograms at the ROIs. The distributions of CVs calculated from the ROI histo-
gram were examined and statistical analysis was carried out. Results: The CV value 
was 0.041±0.009 (mean CV±SD) in the NLF group, while that of cirrhotic group 
was 0.071±0.020. There were statistically significant differences in the CVs and cor-
rected CV values between the NLF and cirrhotic groups (p<0.001). The most accu-
rate cut-off value among CVs for distinguishing normal from cirrhotic group was 
0.052 (sensitivity 83.8% and specificity 88.5%). There was no statistically significant 
differences in SD between NLF and cirrhotic groups (p=0.307). Conclusion: The 
CV of histograms of the hepatobiliary phase on gadoxetate-enhanced MRI may be 
useful as a quantitative value for determining the presence of liver cirrhosis.
Key Words:   Cirrhosis, gadoxetate disodium, magnetic resonance imaging, histo-
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INTRODUCTION
 
The diagnosis of liver fibrosis and cirrhosis in patients with chronic liver disease is 
critical, as cirrhotic patients are at higher risk of developing end stage liver disease, 
portal hypertension, and hepatocellular carcinoma (HCC).1,2 These sequelae are im-
portant causes of morbidity, mortality, and increasing health care costs.3,4 The cumu-
lative incidence of HCC is significantly higher in patients with severe fibrosis than in 
those with no or mild fibrosis.5 Thus, the early detection and accurate staging of he-
patic fibrosis or cirrhosis has become a critical issue in practice. Currently, liver biop-
sy is still the gold standard for the assessment of liver fibrosis. However, liver biopsy 
is invasive, difficult to repeat, and associated with significant patient morbidities. In 
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been studies exploring cirrhosis with histograms of hepato-
biliary phase images using gadoxetate disodium-enhanced 
MR imaging. The purpose of this study was to investigate 
whether histogram analysis of hepatobiliary phase MR im-
aging could be used as a quantitative index for determina-
tion of liver cirrhosis.
MATERIALS AND METHODS
　
Patients 
This retrospective study was compliant with the Health In-
surance Portability and Accountability Act and was approved 
by our Institutional Review Board; the need for patient in-
formed consent was waived. From April 2008 to February 
2011, 285 patients who were suspected of having chronic liv-
er disease or focal hepatic lesions clinically or at previously 
performed US or CT underwent gadoxetate (Eovist, Pri-
movist; Bayer Healthcare Pharmaceuticals, Berlin, Germa-
ny) enhanced liver MRI. Among them, 128 patients were 
examined with a 3T MR scanner. We included the examina-
tions with 3T MR scanners because 3T scanners have bene-
fits in depicting fine details due to its high signal-to-noise 
ratio (SNR) than 1.5T scanners. Sixty-five patients were ex-
cluded for the following reasons: hepatectomy (n=11); poor 
biliary excretion (n=9); and metastatic disease (n=45). We 
excluded the patients with poor biliary excretion because 
adequate hepatobiliary phase images are not typically ob-
tained in these patients.
Finally, a total of 63 patients (28 men, 35 women; age 
range, 21-90 years), including 37 patients with cirrhosis and 
26 patients without liver disease, comprised the study co-
hort. Patients with suspected benign focal liver lesions in 
normal liver parenchyma were classified into a normal liver 
function (NLF) group (n=26). Patients with cirrhosis were 
classified into a cirrhotic group (n=37). The cirrhotic group 
(mean age, 56.7 years; range, 22-90 years) included 22 men 
(mean age, 59.7 years; range, 34-90 years) and 15 women 
(mean age, 52.4 years; range, 22-72 years), and the NLF 
group (mean age, 47.7 years; range, 21-73 years) included 
6 men (mean age, 57.7 years; range, 36-73 years) and 20 
women (mean age, 44.7 years; range, 21-63 years).
The most common etiologies of liver disease were hepati-
tis C, hepatitis B, and alcohol consumption (Table 1). The 
clinical diagnosis of liver cirrhosis was obtained by previous 
histologic examination or was clinically apparent (history, 
laboratory data, imaging study, etc). All NLF and cirrhotic 
addition, liver biopsy is associated with interobserver variabil-
ity and sampling errors.6-8 The search for noninvasive imaging 
methods to assess liver fibrosis and cirrhosis has become an 
important endeavor. Although the presence of cirrhosis can be 
determined on the basis of liver contour abnormalities and 
portal hypertension stigmata using ultrasonography (US), 
computed tomography (CT), and conventional magnetic reso-
nance (MR) imaging, these findings are insensitive in the de-
tection of mild fibrosis and early cirrhosis.9-11 
MR imaging has emerged as a promising modality for the 
assessment of diffuse liver disease. MR imaging provides 
excellent tissue contrast and high sensitivity to the effect of 
contrast agent,12-14 allowing for visualization of hepatic tex-
ture that offers the potential of noninvasively diagnosing cir-
rhosis. Previous studies have reported that fibrosis grades 
can be accurately assessed using superparamagnetic iron 
oxides (SPIO) or double contrast material (SPIO plus gado-
linium chelates) enhanced MR imaging.15,16 Gadoxetate di-
sodium is an MR imaging contrast agent that was developed 
for evaluating the hepatobiliary system.17,18 After intravenous 
injection, gadoxetate disodium is gradually taken up by hepa-
tocytes and is eventually excreted via the biliary system.17 It 
is known that after gadoxetate is intravenously injected, it 
accumulates in hepatocytes and causes T1 shortening, 
which increases liver signal intensity (SI).19 In patients with 
fibrosis, gadoxetate disodium accumulates and causes T1 
shortening preferentially in the spared liver parenchyma, re-
sulting in fibrotic bands appearing relatively hypointense.20,21 
For this reason, it may be possible to diagnose cirrhosis on 
gadoxetate-enhanced MR images on the basis of hepatic 
texture alterations.
A histogram is a useful tool in hepatic texture analysis 
(TA),22,23 as it depicts the distribution of SI levels. We pos-
tulated that cirrhotic liver would show a wider range of SI 
values than normal liver on hepatobiliary phase MR imag-
ing due to fibrotic bands. To our knowledge, there have not 
Table 1. Causes of Liver Disease
Cause No. of patients*
Hepatitis C virus 14 (37)
Hepatitis B virus   8 (22)
Alcohol intake   5 (14)
Nonalcoholic steatohepatitis 3 (8)
Autoimmune hepatitis 1 (3)
Recurrent pyogenic cholangitis 1 (3)
Hemochromatosis 1 (3)
Cryptogenic   4 (10)
*Numbers in parentheses are percentages.
Histogram Analysis of Liver Cirrhosis
Yonsei Med J   http://www.eymj.org   Volume 55   Number 3   May 2014 653
per kilogram of body weight.
Quantitative analysis
MR images were stored in digital imaging and communica-
tions in medicine (DICOM) format. Images were reviewed 
by one abdominal radiologist (J.Y.C.) concerning whether 
there are typical features of liver cirrhosis several morpho-
logic changes including enlargement of the caudate lobe 
and the left lateral segment of the liver, atrophy of the right 
hepatic lobe and the left medial segment, nodularity of the 
liver surface, coarse liver architecture, ascites, splenomega-
ly, and the development of collaterals. The same radiologist 
selected circular, 2 cm2 regions of interest (ROI), avoiding 
vessels and bile ducts. For each patient, images with circu-
lar ROIs were stored on a secondary console containing the 
Osirix DICOM viewer for Macintosh (Osirix, version 3.5.1; 
the Osirix Foundation, Geneva, Switzerland) (Fig. 1). Two 
ROIs were selected on each image from the right hepatic 
lobe and two ROIs from lateral/medial segments of the left 
hepatic lobe at the level of horizontal portion of right portal 
vein. If the ROIs were settled, the standard deviation (SD) 
and mean values within the ROIs were calculated automati-
cally in the viewer. SNRs of the liver on hepatobiliary phase 
MRI scans were calculated as follows: liver SNR=liver SI/
SD of background noise. The four ROIs were used to gener-
ate quantitative measurements of liver texture heterogeneity-
specifically, SD and coefficient of variation (CV).
The CV of standard liver ROI was calculated as follows: 
CV=SDliver/SIliver, where SDliver is the SD of the mean liver 
parenchyma SI and SIliver is the mean SI of the liver paren-
chyma. Based on our observation that cirrhotic liver has a 
more heterogeneous texture (hypointense reticulations against 
a bright liver background) than does the homogeneous nor-
mal liver, the CV was used as a measure of regional liver 
texture heterogeneity. As image noise might contribute to 
variances in liver SI, we also calculated a corrected CV by 
subtracting the SD of the mean air SI from the SD of the 
mean liver parenchyma SI as follows: corrected CV=(SDliver- 
groups underwent standard clinical biochemical testing be-
fore the MR examination. Patients with cirrhosis (n=37) 
were classified into two groups according to Child-Pugh 
classification: a liver cirrhosis with Child-Pugh A group 
(n=33) and a liver cirrhosis with Child-Pugh B group (n=4). 
No patients showed liver cirrhosis with Child-Pugh C status. 
Laboratory data (bilirubin, albumin, and prothrombin time) 
for the NLF and cirrhotic groups are summarized in Table 2.
The NLF group comprised patients with suspected benign 
focal liver lesions (e.g., hemangioma or cyst) in normal liver 
parenchyma. Patients of the NLF group presented with hem-
angiomas (n=11), focal nodular hyperplasia (n=9), cholangi-
tis (n=4), and cysts (n=2). Consecutive patients who met the 
following criteria were included as control subjects: gadox-
etate-enhanced MR imaging performed during the study 
period for indications other than HCC surveillance or dif-
fuse liver disease assessment; no documentation of active 
or past liver disease; no risk factors for liver disease (i.e., 
consumption of two or more alcoholic drinks daily, viral hep-
atitis, and/or drug abuse); NLF test results obtained within 3 
months of the index MR examination; and negative viral 
serology test results (if available). Based on these criteria, 
we judged that focal lesions did not influence liver function 
in these cases.
MR imaging technique
MR imaging was performed using a 3T system (Signa Ex-
cite HD; GE Medical Systems, Milwaukee, WI, USA) with 
an eight-channel torso coil. The basic MR imaging protocol 
consisted of the following imaging sequences: breath hold 
two-dimensional dual echo axial T1-weighted sequence 
[in-phase and out-of-phase; repetition time msec/echo time 
msec, 150/4.2 (in phase) and 150/2.0 (out-of-phase)]; respi-
ratory-triggered two-dimensional fat-suppressed axial T2-
weighted fast spin-echo imaging [1200/72 (effective)]; and 
breath-hold gadoxetate disodium-enhanced hepatic arterial 
dominant, portal venous, and late dynamic phase imaging 
with a fat suppressed three-dimensional gradient echo se-
quence (3.0/1.4; field of view, 24-30×32-40 cm; image ma-
trix, 320×224; flip angle, 15°; section thickness, 3.0-mm 
section thickness, with no gap; acquisition time, 90 sections 
per each phase during 11-second breath hold). Hepatobili-
ary phase imaging was performed with identical MR imag-
ing parameters, except that the acquisition time was 90 sec-
tions during a 22-second breath hold, and the time was 
within 15-25 minutes (mean, 20.5 minutes) after an intrave-
nous bolus injection of gadoxetate disodium, 0.025 mmol 
Table 2. Patient Characteristics
NLF group 
(n=26)
Cirrhosis group 
(n=37)
Age 47.7 56.7
Total bilirubin (mg/dL) 0.56±0.3   1.0±0.7
Albumin (mg/dL) 4.37±0.3   4.0±0.6
Prothrombin time (sec) 12.2±1.0 12.9±1.5
NLF, normal liver function. 
Values indicate mean±standard deviation.
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ble to the cirrhotic group (0.63×0.41 mm) (p>0.05). The 
mean SI±SD of the NLF group was 4146.7± 167.0 (maxi-
mum value 10715.3; minimum value 374.8), while that of 
the cirrhotic group was 1960.6±143.5 (maximum value 
11065.9; minimum value 216.1). There were no statistically 
significant differences in liver SNR between the normal 
group and the cirrhotic group (mean SNR±SD; 37.10±12.7 
for NLF group and 32.34±15.3 for cirrhosis group, p=0.184). 
The mean SI, SD, CV, and corrected CV of the NLF and 
cirrhotic groups are shown in Fig. 2. The SD was 167.0± 
142.1 (mean SD±SD) in the NLF group and 143.5±202.2 in 
the cirrhotic group. There was no statistically significant 
difference in SD between the NLF and cirrhotic groups (p= 
0.307). In the NLF group, the CV value was 0.041±0.009 
(mean CV±SD; maximum value 0.08; minimum value 
0.03). In the cirrhotic group, the CV value was 0.071±0.020 
(mean CV±SD; maximum value 0.17; minimum value 
0.03). The CV values of the cirrhotic group were signifi-
cantly higher than those of the NLF group (p<0.001). The 
CV for the NLF and cirrhotic groups showed a nonnormal 
SDair)/SIliver.15
 
Statistical analysis
Data distributions were tested for normality with Shapiro-
Wilk tests. A comparison of SIliver, SDliver, CVs, and correct-
ed CVs of the groups was carried out using the unpaired 
Student’s t-test. The Spearman’s correlation test was used to 
assess the correlation of CV and corrected CV between NLF 
and cirrhotic groups. The optimal cut-off values of CVs for 
distinguishing normal and cirrhotic groups were calculated. 
The analysis was performed using SPSS software (17.0, 
SPSS Inc., Chicago, IL, USA). All p-values <0.05 were 
considered significant.
RESULTS
 
Of 37 cirrhotic patients, 35 patients showed definite morpho-
logical changes of cirrhosis on visual evaluation. The mean 
pixel size of the NLF group (0.64×0.42 mm) was compara-
Fig. 1. Different histograms of normal function liver and cirrhotic liver on hepatobiliary phase images. (A) Axial T1-weighted hepatobiliary 
phase image obtained after injection of gadoxetate disodium in a 56-year-old woman with normal function liver and a coefficient of varia-
tion (CV) value of 0.035. (B) Histogram of selected region of interest (ROI) on hepatobiliary phase image shows a narrow distribution. The 
horizontal axis represents signal intensity of ROI and vertical axis shows frequency of observations. (C) Axial T1-weighted hepatobiliary 
phase image obtained after injection of gadoxetate disodium in a 48-year-old man with cirrhosis and a CV value of 0.062. (D) Histogram of 
selected ROI on hepatobiliary phase image shows a wide distribution.
A
C
B
D
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distribution (p<0.05, Shapiro-Wilk tests), showing skew-
ness of 1.11 and 0.94, respectively (Fig. 3). The more skewed 
data for the NLF group than cirrhotic group might be ex-
plained by an inhomogeneous group of patients. The kurto-
sis of the NLF group was 2.03, while that of the cirrhotic 
group was 1.95. The Spearman’s correlation test indicated 
that CV values were strongly correlated with the presence 
of cirrhosis with a value of 0.729 (p<0.001). The corrected 
CV values of the cirrhotic group were also higher than the 
NLF group (0.468±0.20 vs. 0.349±0.22) (p<0.001).
Sensitivities and specificities at various CV values were 
calculated for distinguishing normal from cirrhotic patients 
(Table 3). The cut-off value among CVs for distinguishing 
normal from cirrhotic patients with the best accuracy was 
0.052 (sensitivity 83.8% and specificity 88.5%).
DISCUSSION
Our results suggest that histogram analysis of hepatobiliary 
phase MRI can be helpful for differentiating patients with 
NLF and those with cirrhosis. Among the parameters of his-
tograms, CV and corrected CV values of histograms were 
significantly different between NLF and cirrhotic groups. 
Our study suggests that histogram analysis holds the poten-
tial to provide a quantitative index of liver cirrhosis. Cirrho-
sis induces several morphologic changes including enlarge-
ment of the caudate lobe and the left lateral segment of the 
liver, atrophy of the right hepatic lobe and the left medial 
segment, nodularity of the liver surface, coarse liver archi-
tecture, ascites, splenomegaly, and development of collater-
als.9,24-26 However, most are based on morphologic changes 
in the liver that occur late in progression of liver disease or 
secondary signs of portal hypertension. These findings have 
limited utility for the detection of early cirrhosis and the 
grading of advanced fibrosis. The diagnosis of hepatic fi-
brosis of an intermediate degree is difficult because hepatic 
parenchymal textural alterations are often subtle. Although 
there was overlap of CV values between the NLF and cir-
rhotic groups, we were able to reliably differentiate be-
tween the two groups with the CVs of hepatobiliary phase 
imaging. Our study also introduced a simple and practical 
method for determining the distribution of pixel values. 
With our method, the SD and average value of ROIs can be 
measured with the picture archiving and communication 
system (PACS) and the CV can be easily calculated. Ac-
cordingly, we suggest that CVs of the hepatobiliary phase 
Fig. 2. Box plots show the results of analysis of (A) the SD, (B) CV values, 
and (C) corrected CV for the NLF and cirrhotic groups. Each box stretches 
from the 25th percentile at lower edge to the 75th percentile at upper edge; 
the median is shown as a line across the box. There are two adjacent val-
ues below and above the box: the largest value is below the upper inner 
limit and the smallest value is above the lower inner limit. Outside values 
below or above the inner limit but within the outer limit are outliers. Star 
marks in Fig. 2A indicates outlying values meaning wide range of pixel val-
ues in cirrhosis. SD, standard deviation; CV, coefficient of variation; NLF, 
normal liver function.
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Watanabe, et al.21 reported that contrast enhancement index 
on gadoxetate disodium-enhanced MR imaging is more re-
liable for staging hepatic fibrosis than diffusion-weighted 
MR imaging and clinical parameters. Our results suggest that 
liver cirrhosis can be accurately evaluated using TA of the 
hepatobiliary phase. With a cut-off value of 0.052, sensitivity 
and specificity values greater than 84% were achieved. Com-
bined texture and secondary imaging features would likely 
further improve diagnostic performance, although this was 
not evaluated in this study. Moreover, as contrast agent en-
hanced MRI is part of routine techniques for liver imaging, 
there is no need to acquire additional sequences such as dif-
fusion-weighted sequence or MR elastography.
A histogram is a graphical representation of the distribu-
tion of data.22,23 Histograms can be computed in the PACS 
program, which makes it possible to assess the distribution 
of each pixel value. In PACS, the SI value within a ROI is 
shown on the monitor by an automatic calculation of the 
selected ROI. The histogram illustrates how the pixels in an 
image are distributed by graphing the number of pixels, 
while the SD represents the variation in the SI values. The 
vertical axis shows the total number of pixels with a given 
value. The CV is a normalized measure of dispersion of a 
probability distribution that can be used when comparing 
between data sets with different units or widely different 
means. The CV values of the hepatobiliary phase on gadox-
etate disodium-enhanced MRI that are calculated on the 
ROI histogram reflect the homogeneity or heterogeneity of 
the hepatic parenchyma. Smaller CV values are thought to 
represent normal liver, while larger CV values reflect the 
can be used as a screening measurement tool for evaluating 
hepatic parenchymal texture and aid in the diagnosis of cir-
rhosis in daily practice. 
Biopsy remains the clinical reference standard for the di-
agnosis of liver fibrosis. Serum biomarkers for liver fibrosis 
have been described, but their clinical effectiveness has not 
been established. The development of noninvasive imaging 
methods to detect fibrosis has become a major interest for 
clinicians who hope for more efficient and effective serial 
follow-up of patients, documentation of temporal changes, 
and assessment of therapy response. Some investigators 
have proposed that it may be possible to diagnosis and grade 
fibrosis with MR imaging by measuring viscoelasticity27-29 
or water diffusion.21,30 A different approach is to directly vi-
sualize fibrotic tissue. In previous reports, fibrosis has been 
depicted as hyperintense reticulations against a hypointense 
liver background after the administration of SPIOs or combi-
nation of SPIO and gadolinium-based contrast material.15,16,31 
The hyperintense reticulations, which are postulated to rep-
resent septal fibrosis, can be observed in cirrhotic liver tis-
sue. Gadoxetate disodium-enhanced MR imaging has been 
suggested as a reliable method for staging hepatic fibrosis. 
Table 3. Various Cut-Off Values of CV to Distinguish Normal 
Liver Function from Cirrhosis
Cut-off 
  values
0.03 0.04 0.05 0.052 0.06 0.07 0.08
Sensitivity 99.3 98.0 88.5 83.8 68.9 44.6 27.0
Specificity   9.6 55.8 78.8 88.5 95.2 99.0 99.0
CV, coefficient of variation.
Values of sensitivity and specificity indicate percentage (%). 
Fig. 3. Histograms of NLF and cirrhosis groups. (A) The CV for NLF group showed a normal distribution, showing a skewness value of 1.11. (B) The CV for cir-
rhosis group showed a normal distribution, showing a skewness value of 0.94. CV, coefficient of variation; NLF, normal liver function.
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ic fibrosis. Third, the enhancement of hepatobiliary phase 
depends on several factors although organic anionic trans-
port polypeptides 8 (OATP8, also known as OATP1B1/3) 
are the dominant determinant.34 OATP8 is thought to be re-
sponsible for uptake by hepatocytes of gadoxetic acid.35 
OATP8 represent members of the OATP superfamily that 
mediate the sodium-independent hepatic uptake of a di-
verse range of organic compounds including bile acids, thy-
roid hormones, bilirubin gluconides, steroid conjugates, and 
numerous drugs such as statins or sartans.36 Therefore, he-
patic uptake of gadoxetic acid may be influenced in patients 
taking these organic compounds because of competitive 
uptake. Also the SNR of the hepatobiliary phase may be in-
fluenced by modulating the flip angle. Increasing the flip 
angle in the hepatobiliary phase T1-weighted imaging in-
creases the SNR of the liver, while decreasing the SNR of 
non-hepatocyte-containing tissues such as fibrosis results in 
an increased lesion to liver CNR with subsequent improved 
lesion conspicuity.37 This effect is due to an increase in T1-
weighting, resulting in an increase in contrast between he-
patic fibrotic tissues and functioning hepatic parenchy-
ma.38,39 Thus the quantitative value in our study may not be 
applied equally when flip angle is modulated from its con-
ventional setting (10-15°). Fourth, the pixel size of hepato-
biliary phase was not exactly the same in each patient. 
However, the pixel size was comparable in both groups and 
there was no statistical difference therein between the two 
groups. Fifth, we did not evaluate the interobserver vari-
ability of the measurement of ROIs. This issue should be 
further studied in a larger series. Finally, we excluded pa-
tients with impaired hepatic enhancement because this 
group of patients cannot be effectively imaged with gadox-
etate disodium-enhanced MRI. Considering that hepatic 
function is closely related to hepatic uptake of gadoxetate, 
this may have introduced a component of selection bias to 
our study. 
In conclusion, the histogram analysis of hepatobiliary 
phase MRI reflects the homogeneity or heterogeneity of the 
hepatic parenchyma. The CV values of histogram on hepa-
tobiliary phase can be used as a quantitative value that can 
determine the presence of liver cirrhosis. 
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possibility of cirrhotic liver in which with fibrotic bands are 
thought to cause reflections of various signal intensities. Al-
though differences in the CV values between NLF and cir-
rhotic groups were observed, there was definite overlap of 
CV values between NLF and cirrhotic groups. This was 
presumably because variable stages of fibrosis were includ-
ed in this study and small vessels or bile ducts could have 
been included in the ROIs. The evaluation of fibrosis, there-
fore, depends on the choice of ROI, which should be im-
proved in the future.
Texture refers to the distribution of brightness and dark-
ness within the image. TA is based on the quantification of 
complex mathematical patterns, which exist in the gray-
level distribution of the pixels of images. TA evaluates the 
spatial location and SI of each pixel in the examined area.32 
There are many features that can be applied for TA. Among 
them, the statistical measurement methods represent the sta-
tistical aspect of texture evaluation, concerning the interre-
lationships among pixels. Other texture feature analysis ap-
proaches are based on models. Jirák, et al.32 reported that the 
best discriminative feature for differentiating cirrhosis from 
normal was kurtosis; other differentiating features included 
difference entropy, gradient skewness, and skewness. Com-
bination of texture parameters such as mean gray-scale val-
ue, contrast, angular second moment, or entropy have also 
been used for differentiating hepatic fibrosis from normal 
liver.33 CV and corrected CV have been suggested as accu-
rate quantitative scores for liver texture features.15 Our TA is 
based only on the variability of SI on hepatobiliary phase 
images. More sophisticated texture features can be assessed 
and may facilitate better performance. Regarding the se-
quence of MR imaging, the equilibrium phase after admin-
istration of gadolinium-based contrast agent has been sug-
gested to reflect the degree of fibrosis most accurately.33 
Compared to equilibrium phase of gadolinium-based con-
trast agent, hepatobiliary phase images using gadoxetate di-
sodium have better contrast-to-noise ratio (CNR), resulting 
in superior conspicuity for fibrotic bands in cirrhotic liver. 
Therefore, hepatobiliary phase imaging may be the optimal 
sequence for evaluating TA. 
Our study was limited by its retrospective design and in-
clusion of cirrhotic patients who had advanced fibrosis with 
obvious imaging stigmata of liver disease or based on clini-
cal findings. Second, we could not analyze the data accord-
ing to the grade of fibrosis because no histopathologic proof 
was obtained for cirrhotic patients. Further studies are need-
ed to determine if this method can be used in grading hepat-
Jin-Young Choi, et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 3   May 2014658
ing. Radiology 1995;195:785-92.
18. Reimer P, Rummeny EJ, Shamsi K, Balzer T, Daldrup HE, Tom-
bach B, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, 
safety aspects, and pulse sequence. Radiology 1996;199:177-83.
19. Ni Y, Marchal G, Lukito G, Yu J, Mühler A, Baert AL. MR imag-
ing evaluation of liver enhancement by Gd-EOB-DTPA in selec-
tive and total bile duct obstruction in rats: correlation with sero-
logic, microcholangiographic, and histologic findings. Radiology 
1994;190:753-8.
20. Tsuda N, Okada M, Murakami T. New proposal for the staging of 
nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-
EOB-DTPA-enhanced MRI. Eur J Radiol 2010;73:137-42. 
21. Watanabe H, Kanematsu M, Goshima S, Kondo H, Onozuka M, 
Moriyama N, et al. Staging hepatic fibrosis: comparison of gadox-
etate disodium-enhanced and diffusion-weighted MR imaging--
preliminary observations. Radiology 2011;259:142-50. 
22. Sãftoiu A, Gheonea DI, Ciurea T. Hue histogram analysis of real-
time elastography images for noninvasive assessment of liver fi-
brosis. AJR Am J Roentgenol 2007;189:W232-3.
23. Maeda K, Utsu M, Kihaile PE. Quantification of sonographic 
echogenicity with grey-level histogram width: a clinical tissue 
characterization. Ultrasound Med Biol 1998;24:225-34.
24. Aubé C, Oberti F, Korali N, Namour MA, Loisel D, Tanguy JY, et 
al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J 
Hepatol 1999;30:472-8.
25. Brancatelli G, Federle MP, Ambrosini R, Lagalla R, Carriero A, 
Midiri M, et al. Cirrhosis: CT and MR imaging evaluation. Eur J 
Radiol 2007;61:57-69.
26. Ito K, Mitchell DG, Siegelman ES. Cirrhosis: MR imaging fea-
tures. Magn Reson Imaging Clin N Am 2002;10:75-92.
27. Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Ross-
man PJ, et al. Assessment of hepatic fibrosis with magnetic reso-
nance elastography. Clin Gastroenterol Hepatol 2007;5:1207-13.
28. Asbach P, Klatt D, Hamhaber U, Braun J, Somasundaram R, 
Hamm B, et al. Assessment of liver viscoelasticity using multifre-
quency MR elastography. Magn Reson Med 2008;60:373-9. 
29. Huwart L, Sempoux C, Salameh N, Jamart J, Annet L, Sinkus R, 
et al. Liver fibrosis: noninvasive assessment with MR elastogra-
phy versus aspartate aminotransferase-to-platelet ratio index. Ra-
diology 2007;245:458-66.
30. Annet L, Peeters F, Abarca-Quinones J, Leclercq I, Moulin P, Van 
Beers BE. Assessment of diffusion-weighted MR imaging in liver 
fibrosis. J Magn Reson Imaging 2007;25:122-8.
31. Faria SC, Ganesan K, Mwangi I, Shiehmorteza M, Viamonte B, 
Mazhar S, et al. MR imaging of liver fibrosis: current state of the 
art. Radiographics 2009;29:1615-35. 
32. Jirák D, Dezortová M, Taimr P, Hájek M. Texture analysis of hu-
man liver. J Magn Reson Imaging 2002;15:68-74.
33. Kato H, Kanematsu M, Zhang X, Saio M, Kondo H, Goshima S, 
et al. Computer-aided diagnosis of hepatic fibrosis: preliminary 
evaluation of MRI texture analysis using the finite difference 
method and an artificial neural network. AJR Am J Roentgenol 
2007;189:117-22.
34. Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, Koda W, 
et al. The uptake transporter OATP8 expression decreases during 
multistep hepatocarcinogenesis: correlation with gadoxetic acid 
enhanced MR imaging. Eur Radiol 2011;21:2056-66. 
35. Tsuboyama T, Onishi H, Kim T, Akita H, Hori M, Tatsumi M, et 
al. Hepatocellular carcinoma: hepatocyte-selective enhancement 
at gadoxetic acid-enhanced MR imaging--correlation with expres-
REFERENCES
1. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise re-
view. Am J Gastroenterol 2004;99:1160-74.
2. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838-51. 
3. Buti M, San Miguel R, Brosa M, Cabasés JM, Medina M, Angel 
Casado M, et al. Estimating the impact of hepatitis C virus therapy 
on future liver-related morbidity, mortality and costs related to 
chronic hepatitis C. J Hepatol 2005;42:639-45.
4. Talwalkar JA. Economic impact of hospitalization for end-stage 
liver disease. Am J Gastroenterol 2002;97:1562.
5. Tokita H, Fukui H, Tanaka A, Kamitsukasa H, Yagura M, Harada 
H, et al. Risk factors for the development of hepatocellular carci-
noma among patients with chronic hepatitis C who achieved a 
sustained virological response to interferon therapy. J Gastroenter-
ol Hepatol 2005;20:752-8.
6. Froehlich F, Lamy O, Fried M, Gonvers JJ. Practice and compli-
cations of liver biopsy. Results of a nationwide survey in Switzer-
land. Dig Dis Sci 1993;38:1480-4.
7. Perrault J, McGill DB, Ott BJ, Taylor WF. Liver biopsy: compli-
cations in 1000 inpatients and outpatients. Gastroenterology 
1978;74:103-6.
8. Terjung B, Lemnitzer I, Dumoulin FL, Effenberger W, Brackmann 
HH, Sauerbruch T, et al. Bleeding complications after percutane-
ous liver biopsy. An analysis of risk factors. Digestion 2003;67: 
138-45.
9. Ito K, Mitchell DG. Imaging diagnosis of cirrhosis and chronic 
hepatitis. Intervirology 2004;47:134-43.
10. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, 
Schick F. Non-invasive assessment and quantification of liver ste-
atosis by ultrasound, computed tomography and magnetic reso-
nance. J Hepatol 2009;51:433-45.
11. Vitellas KM, Tzalonikou MT, Bennett WF, Vaswani KK, Bova 
JG. Cirrhosis: spectrum of findings on unenhanced and dynamic 
gadolinium-enhanced MR imaging. Abdom Imaging 2001;26: 
601-15.
12. Hammerstingl R, Zangos S, Schwarz W, Rosen T, Bechstein WO, 
Balzer T, et al. Contrast-enhanced MRI of focal liver tumors using 
a hepatobiliary MR contrast agent: detection and differential diag-
nosis using Gd-EOB-DTPA-enhanced versus Gd-DTPA-enhanced 
MRI in the same patient. Acad Radiol 2002;9 Suppl 1:S119-20.
13. Talwalkar JA, Yin M, Fidler JL, Sanderson SO, Kamath PS, Ehm-
an RL. Magnetic resonance imaging of hepatic fibrosis: emerging 
clinical applications. Hepatology 2008;47:332-42.
14. Bluemke DA, Sahani D, Amendola M, Balzer T, Breuer J, Brown 
JJ, et al. Efficacy and safety of MR imaging with liver-specific 
contrast agent: U.S. multicenter phase III study. Radiology 2005; 
237:89-98.
15. Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liv-
er fibrosis: noninvasive diagnosis with double contrast material-
enhanced MR imaging. Radiology 2006;239:425-37.
16. Lucidarme O, Baleston F, Cadi M, Bellin MF, Charlotte F, Ratziu 
V, et al. Non-invasive detection of liver fibrosis: is superparamag-
netic iron oxide particle-enhanced MR imaging a contributive 
technique? Eur Radiol 2003;13:467-74.
17. Hamm B, Staks T, Mühler A, Bollow M, Taupitz M, Frenzel T, et 
al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobili-
ary MR contrast agent: safety, pharmacokinetics, and MR imag-
Histogram Analysis of Liver Cirrhosis
Yonsei Med J   http://www.eymj.org   Volume 55   Number 3   May 2014 659
and detection rate of hypointense lesions? J Magn Reson Imaging 
2012;35:611-6. 
38. Stelter L, Grieser C, Fernándes CM, Rothe JH, Streitparth F, See-
hofer D, et al. Flip angle modulations in late phase Gd-EOB-DT-
PA MRI improve the identification of the biliary system. Eur J Ra-
diol 2012;81:e991-5. 
39. Bashir MR, Merkle EM. Improved liver lesion conspicuity by in-
creasing the flip angle during hepatocyte phase MR imaging. Eur 
Radiol 2011;21:291-4.
 
sion of sinusoidal and canalicular transporters and bile accumula-
tion. Radiology 2010;255:824-33.
36. Nassif A, Jia J, Keiser M, Oswald S, Modess C, Nagel S, et al. Vi-
sualization of hepatic uptake transporter function in healthy sub-
jects by using gadoxetic acid-enhanced MR imaging. Radiology 
2012;264:741-50.
37. Bashir MR, Husarik DB, Ziemlewicz TJ, Gupta RT, Boll DT, 
Merkle EM. Liver MRI in the hepatocyte phase with gadolinium-
EOB-DTPA: does increasing the flip angle improve conspicuity 
